The establishment of EVISA is funded by the EU through
the Fifth Framework Programme (G7RT- CT- 2002- 05112).
Supporters of EVISA includes:
compound with immune adjuvant activity. This agent adsorbs and
preciptates protein antigens in solution; the resulting precipitate
improves vaccine immunogenicity by faclitating the slow release of
antigen from the vaccine depot formed at the site of inoculation